Ypsomed 2023/24 Half-Year Results

We deliver

Webcast, 15 November 2023

PUBLIC

Important information

The information contained in this document has not been verified by an independent source. It should be taken with caution and no assurance or guarantee is given (either explicit or implied) with regard to the fairness, accuracy, completeness or correctness of the information or opinions contained herein. Neither Ypsomed Holding AG nor advisors or affiliates of Ypsomed Holding AG shall be liable in any way for losses occurred in conjunction with the use of this document, its contents or any other connection with this document. This document is neither an offer (or part of an offer) for the sale, nor a solicitation for the purchase of shares, and neither the document nor parts thereof form the basis of any contract or otherwise obligation. This document contains future-oriented statements which include uncertainties and risks. Such statements are indicated by such words as "could", "planned", "expected", "believed" and similar expressions or their context. These statements are made based on current knowledge and current assumptions. Due to a variety of different factors, the actual future results, developments or events may deviate considerably from those mentioned here. There is no obligation whatsoever to update future- oriented statements.

2 | Ypsomed Holding AG | 2023/24 Half-Year Results

PUBLIC

Making selfcare simpler and easier

Improved therapy outcomes for chronic conditions

3 | Ypsomed Holding AG | 2023/24 Half-Year Results

PUBLIC

Solutions for healthcare's biggest challenge are our growth drivers

  • Selfcare
    Improving quality of life, therapy adherence and supporting affordable healthcare systems
  • Biologics
    Most new-generation drugs with complex active pharmaceutical ingredients must be injected
  • Biosimilars
    Expanding global access to affordable medical care
  • Digitization
    Enabling innovative, digital therapy management for optimal therapy outcomes and evidence-based care

4 | Ypsomed Holding AG | 2023/24 Half-Year Results

PUBLIC

Purpose and ambition

  • Growth drivers are lasting
  • Focused portfolio allows margin expansion
  • No "GLP-1 risk", in contrary
  • Continuous investment in innovation, capacity expansion and employee
  • Portfolio review ongoing

5 | Ypsomed Holding AG | 2023/24 Half-Year Results

PUBLIC

Turnover growth of 24 % from continued business

Ypsomed Group

Mail-order company DiaExpert GmbH in Germany was sold on 31 December 2022

6 | Ypsomed Holding AG | 2023/24 Half-Year Results

PUBLIC

Remarkable gross margin expansion

Higher utilisation of production capacities

Since 01 January 2023, absence of dilution by divested DiaExpert's trading business

7 | Ypsomed Holding AG | 2023/24 Half-Year Results

PUBLIC

Significant rise in EBIT from HY 2022/23 to HY 2023/24

8 | Ypsomed Holding AG | 2023/24 Half-Year Results

PUBLIC

Confirming outlook for the 2023/24 financial year

  • For the 2023/24 financial year, Ypsomed expects sales growth of the continued business of around 25 %
  • At EBIT level, Ypsomed confirms the outlook and expects an operating profit of at least CHF 90 million

9 | Ypsomed Holding AG | 2023/24 Half-Year Results

PUBLIC

10 Ypsomed Holding AG | 2023/24 Half-Year Results

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

Ypsomed Holding AG published this content on 15 November 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 15 November 2023 10:08:07 UTC.